Betta Pharmaceuticals Co., Ltd. (SHE: 300558) and Hangzhou Gensciences Biopharmaceuticals Co., Ltd. announced a collaboration under which Betta Pharmaceuticals has acquired the global exclusive rights to the ultra‑long‑acting monthly growth hormone formulation (SS202) project, including technical data and rights to the specific molecule, its preparation, and its applications – with Betta set to fully lead global research and development, manufacturing, and commercialization of the product.
Transaction Overview
| Item | Detail |
|---|---|
| Parties | Betta Pharmaceuticals Co., Ltd. (SHE: 300558); Hangzhou Gensciences Biopharmaceuticals Co., Ltd. |
| Transaction Type | Global exclusive license / acquisition of project rights |
| Asset | SS202 – ultra‑long‑acting monthly growth hormone formulation |
| Rights Acquired | Technical data; rights to the molecule, preparation, and applications; full leadership of global R&D, manufacturing, and commercialization |
| Upfront Payment | RMB 10 million |
| Milestone Payments | RMB 40 million |
| Royalties | Share of commercial sales after product launch |
| Announcement Date | 29 Oct 2026 |
Drug Profile & Mechanism of Action
- Molecule: SS202 – an ultra‑long‑acting recombinant growth hormone candidate drug.
- Intended Indications: Idiopathic short stature, pediatric and adult growth hormone deficiency (GHD), and Turner syndrome.
- Technology Platform: An innovative dual long‑acting technology combining Fc fusion and fatty acid conjugation, designed to extend systemic exposure and enable once‑monthly administration – a potential step beyond the weekly dosing of currently marketed long‑acting growth hormones.
- Clinical Value Proposition: Monthly dosing would substantially reduce annual injection burden versus daily recombinant growth hormone therapy, addressing a key adherence and quality‑of‑life limitation in pediatric and adult endocrinology.
Development Status
| Stage | Status |
|---|---|
| Key Druggability Studies | Completed |
| Preclinical Candidate (PCC) | Molecule locked in |
| Current Phase | Formally entered IND‑enabling research stage |
| Clinical Trial Timeline | Not disclosed |
Market Impact & Outlook
- Long‑Acting Growth Hormone Landscape: The market has shifted toward long‑acting formulations that replace daily injections; an ultra‑long‑acting monthly candidate would compete on dosing convenience at the aggressive end of the spectrum if successful.
- Pipeline Diversification: The deal extends Betta Pharmaceuticals – developer of China’s first homegrown innovative oncology drug, icotinib – beyond oncology into endocrinology and rare disease, adding a wholly owned global asset in the growth hormone space.
- Deal Economics: The structure (RMB 10 million upfront, RMB 40 million milestones, plus sales royalties) reflects the asset’s early‑stage, preclinical status while aligning Gensciences with downstream development success.
- Execution Risk: SS202 remains in IND‑enabling research; commercialization depends on IND approval, clinical outcomes, and regulatory review, none of which are yet assured.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory timelines, clinical outcomes, and commercial expectations for SS202. Actual results may differ due to risks including IND‑enabling study findings, clinical trial execution, safety profile, subsequent regulatory review requirements, and competitive dynamics in the growth hormone market.-Fineline Info & Tech
